Skip to content

Edgewise Therapeutics, Inc.

EWTX

CIK 0001710072

← back to feed
Revenue (TTM)
—
Q1 Apr 2026
Net Income (TTM)
−$166.59M
−25.4% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$1.62
−12.4% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
—
Q1 Apr 2026
Net Margin
—
Q1 Apr 2026
Free Cash Flow (TTM)
−$136.8M
Q1 Apr 2026
Cash
$33.21M
Q1 Apr 2026
Total Debt
$66K
Q1 Apr 2026
Shares Outstanding
107.59M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings